Cardiol Therapeutics company info

What does Cardiol Therapeutics do?
Cardiol Therapeutics (TSX:CRDL), (NASDAQ:CRDL) is a biotechnology company focused on researching and developing innovative cannabidiol (CBD) treatments for heart diseases and other medical conditions. With a commitment to scientific excellence, Cardiol's projects include the development of anti-inflammatory therapies aimed at reducing the risk of cardiovascular diseases and improving patient outcomes. The company's objectives center around leveraging their proprietary technologies and pharmaceutical expertise to lead the way in developing safer, more effective CBD-based medicines. Cardiol Therapeutics Class A is also traded on the Nasdaq under the ticker code (NASDAQ:CRDL), enabling a broader international investment base to support its mission in transforming cardiovascular treatment landscapes.
Cardiol Therapeutics  company media
Company Snapshot

Is Cardiol Therapeutics a public or private company?

key
Ownership
Public

How many people does Cardiol Therapeutics employ?

people
Employees
26

What sector is Cardiol Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Cardiol Therapeutics ?

location pin
Head Office
Oakville, Canada

What year was Cardiol Therapeutics founded?

founded flag
Year Founded
2017
What does Cardiol Therapeutics specialise in?
/Pharmaceutical Development /Heart Medicines /CBD Therapy /Clinical Research /Healthcare Services /Drug Commercialization

What are the products and/or services of Cardiol Therapeutics ?

Overview of Cardiol Therapeutics offerings
Development of CardiolRx, a pharmaceutically produced cannabidiol formulation for treating heart failure and inflammatory heart disease.
Clinical trials for anti-fibrotic and anti-inflammatory therapies targeting cardiovascular diseases.
Research on small molecules for treating fibrotic diseases, including myocarditis and heart failure.
Collaboration on the formulation and clinical development of new drug candidates designed to protect heart tissue after acute events.
Partnerships for advancing the development of diagnostic and therapeutic technologies in cardiovascular medicine.
Outreach and education initiatives aimed at increasing awareness of heart diseases and the potential benefits of cannabidiol-based treatments.

Who is in the executive team of Cardiol Therapeutics ?

Cardiol Therapeutics leadership team
  • Mr. David G. Elsley MBA
    Mr. David G. Elsley MBA
    President, CEO & Director
  • Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA
    Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA
    CFO, Corporate Secretary & Director
  • Mr. Bernard  Lim B.Sc.
    Mr. Bernard Lim B.Sc.
    Chief Operating Officer
  • Dr. Andrew Warwick Hamer M.D.
    Dr. Andrew Warwick Hamer M.D.
    Chief Medical Officer & Head of Research & Development
  • Trevor  Burns
    Trevor Burns
    Investor Relations